Skip to content
Aussie8 – Lifestyle
Author:
Biovica International
Biovica Granted Japanese Patent for Immuno-Oncology
July 1, 2026
Correction: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
June 30, 2026
Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
June 30, 2026
Biovica International AB – Annual Report for The Financial Year 2025/2026 Published
June 30, 2026
Year-End Report 2025-2026
June 17, 2026
New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer
May 28, 2026
Biovica Receives Expanded Work Order from Clinical-Stage Oncology Company for Next-Generation CDK Inhibitor Program
May 26, 2026
Biovica International AB Announces Change in Executive Management
May 5, 2026
New ESMO Data Highlights TKa Across Multiple Treatment Settings
April 30, 2026
Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026
April 16, 2026
1
2
Next Page
→